Nav: Home

Breast cancer: The promises of old recipes

March 28, 2019

Of the three major subtypes of breast cancer, the «triple negative» is the most lethal: half of all breast cancer deaths are attributed to it, whereas it accounts for only about 15% of incidences of breast cancer. And unlike other breast cancers, it is resistant to most existing therapies. By studying the properties of clofazimine, a 70-year-old antibiotic, scientists from the Universities of Geneva (UNIGE) and Lausanne (UNIL), in Switzerland, demonstrate its effectiveness in stopping the progression of the disease in in vivo tests. Indeed, it blocks the Wnt cell signalling pathway - a disruption of the cell mechanism that causes many cancers, including triple negative breast cancer. These results, to be read in Cancer Letters, highlight the need to re-examine with a fresh eye the drugs already on the market, especially the older ones.

Triple negative breast cancer is a particularly aggressive form of breast cancer, affecting especially young women. Its very rapid progression and the lack of effective treatment thus contribute to making it an extremely serious disease, causing the death of more than 200,000 women worldwide each year.

Better targeting for better care

Increasingly, cancer specialists are seeking to develop therapies that specifically target cancer cells but that would spare healthy cells. Vladimir Katanaev, Professor at the Faculty of Medicine Translational Research Centre in Oncohaematology (CRTOH) of the UNIGE, who directed this work, explains the principle behind it: "The idea is to identify molecular elements specific to tumour cells, but absent from healthy cells, and precisely target them. These elements - called oncogenes - are necessary to transform healthy cells into malignant cells, so it is important to bring them down without damaging neighbouring cells."

In the case of triple negative breast cancer, as well as in other cancers such as liver or colon cancer, one of the main suspects is the Wnt signalling pathway. When cells communicate with each other, they do so through chemical signals, i.e. the signalling pathways. The cell that receives the signal responds to it by migrating, for example, or by dividing. The Wnt signalling pathway is essential during embryogenesis by allowing the unborn baby to develop properly. In adults, however, it usually shuts down and its reactivation - following a mutation or epigenetic modification - gives an erroneous growth signal and allows tumour development. However, if Wnt is blocked, tumour growth stops.

A very old antibiotic with unsuspected capacities

In 2014, Professor Katanaev's team (at UNIL back then) had shown in vitro the inhibitory effect of clofazimine on the Wnt signalling pathway in triple negative breast cancer. They now confirm this effect in vivo, in animal models of the disease: "With clofazimine, tumour growth is significantly reduced", says Vladimir Katanaev. "In addition, we did not detect any adverse side effects, an essential aspect of drug development process."

The researchers also demonstrated that clofazimine targets the Wnt signaling pathway well in vivo, as expected. In addition, clofazimine is even more effective when administered in combination with doxorubicin, a conventional chemotherapeutic drug. Alexey Koval, a researcher at the CRTOH of the UNIGE at the Faculty of Biology and Medicine of the UNIL and co-first author of this study, analyses these results: "Clofazimine acts as an inhibitor of the Wnt signaling pathway: the sick cell can no longer divide, but does not die. Doxorubicin, on the other hand, kills cells that have stopped growing. A combination of great efficacy!"

Is drug repositioning the future of pharmacology?

Many researchers around the world have undertaken to review existing drugs in the light of new technologies and methodologies now available, in order to discover unknown effects. The repositioning of drugs, for which testing and marketing procedures are simpler than for entirely new molecules, saves time and costs less. Clofazimine, an antibacterial agent used to fight leprosy, has been on the market for a long time and is, in fact, in the public domain. "This very inexpensive drug is even on the WHO's list of essential medicines and is produced all over the world, including in Switzerland," adds Vladimir Katanaev. "This is an advantage, of course, but it also complicates the fundraising required to continue our work: indeed, no patent can be filed."

The next step is now to conduct clinical trials involving volunteer patients, first in Geneva, then likely elsewhere in Switzerland.

Université de Genève

Related Breast Cancer Articles:

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
More Breast Cancer News and Breast Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at